Nephros (NEPH) Competitors $4.26 +0.05 (+1.19%) Closing price 09/12/2025 03:57 PM EasternExtended Trading$4.23 -0.03 (-0.70%) As of 09/12/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. CV, AVR, INO, LNSR, LAKE, LUCD, BSGM, PROF, PDEX, and SPAIShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include CapsoVision (CV), Anteris Technologies Global (AVR), Inovio Pharmaceuticals (INO), LENSAR (LNSR), Lakeland Industries (LAKE), Lucid Diagnostics (LUCD), Biosig Technologies (BSGM), Profound Medical (PROF), Pro-Dex (PDEX), and Safe Pro Group (SPAI). These companies are all part of the "medical equipment" industry. Nephros vs. Its Competitors CapsoVision Anteris Technologies Global Inovio Pharmaceuticals LENSAR Lakeland Industries Lucid Diagnostics Biosig Technologies Profound Medical Pro-Dex Safe Pro Group CapsoVision (NASDAQ:CV) and Nephros (NASDAQ:NEPH) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends. Does the media favor CV or NEPH? In the previous week, Nephros had 1 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for Nephros and 2 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.47 beat Nephros' score of 0.73 indicating that CapsoVision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of CV or NEPH? 41.1% of Nephros shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, CV or NEPH? Nephros has higher revenue and earnings than CapsoVision. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapsoVision$12.52M15.40N/AN/AN/ANephros$16.68M2.71$70K$0.1235.50 Is CV or NEPH more profitable? Nephros has a net margin of 7.95% compared to CapsoVision's net margin of 0.00%. Nephros' return on equity of 14.89% beat CapsoVision's return on equity.Company Net Margins Return on Equity Return on Assets CapsoVisionN/A N/A N/A Nephros 7.95%14.89%11.64% Do analysts rate CV or NEPH? CapsoVision currently has a consensus target price of $5.50, suggesting a potential upside of 33.50%. Nephros has a consensus target price of $5.50, suggesting a potential upside of 29.11%. Given CapsoVision's stronger consensus rating and higher probable upside, equities analysts clearly believe CapsoVision is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CapsoVision 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Nephros 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNephros beats CapsoVision on 8 of the 13 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.16M$10.78B$5.86B$10.14BDividend YieldN/A1.84%5.68%4.60%P/E Ratio35.5021.1375.2025.97Price / Sales2.7129.99514.97181.13Price / Cash210.3824.8137.5660.44Price / Book5.263.5212.156.29Net Income$70K$210.50M$3.29B$270.96M7 Day Performance11.23%-0.18%0.75%3.87%1 Month Performance3.40%1.09%4.82%4.88%1 Year Performance128.74%-10.96%60.59%26.12% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros3.2119 of 5 stars$4.26+1.2%$5.50+29.1%+127.2%$45.16M$16.68M35.5030Positive NewsShort Interest ↓Gap DownCVCapsoVisionN/A$3.58-1.6%$5.50+53.6%N/A$167.44MN/A0.0090News CoveragePositive NewsGap DownAVRAnteris Technologies Global1.7268 of 5 stars$4.46-3.9%$16.50+270.0%N/A$160.84M$2.48M0.00138News CoveragePositive NewsINOInovio Pharmaceuticals3.7415 of 5 stars$2.75-4.4%$8.80+220.6%-64.1%$146.40M$220K-1.06320Positive NewsLNSRLENSAR1.5447 of 5 stars$12.18-1.3%$15.00+23.2%+148.4%$145.37M$53.49M-2.89110News CoveragePositive NewsLAKELakeland Industries4.8405 of 5 stars$14.48-3.5%$26.00+79.5%-27.4%$137.49M$177.65M-4.802,100News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionLUCDLucid Diagnostics3.1811 of 5 stars$1.26+2.4%$3.65+190.8%+23.3%$136.14M$4.35M-1.0570News CoverageBSGMBiosig Technologies2.2266 of 5 stars$4.05+4.4%$10.00+146.9%+1,316.6%$126.78M$40K0.0050Gap DownPROFProfound Medical2.2177 of 5 stars$4.09-0.6%$11.00+169.3%-48.9%$122.75M$10.68M-2.80150Positive NewsPDEXPro-Dex2.728 of 5 stars$37.26+4.8%$56.00+50.3%+26.7%$121.47M$66.59M13.80140Positive NewsSPAISafe Pro Group3.3568 of 5 stars$6.95+7.9%$10.50+51.1%+183.9%$112.37M$1.50M-8.6911Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies CapsoVision Competitors Anteris Technologies Global Competitors Inovio Pharmaceuticals Competitors LENSAR Competitors Lakeland Industries Competitors Lucid Diagnostics Competitors Biosig Technologies Competitors Profound Medical Competitors Pro-Dex Competitors Safe Pro Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEPH Stock Alerts